Table 2 Gene set enrichment analysis (GSEA) of CLL B cells from fludarabine-sensitive and -resistant patients

STRESS_ARSENIC_SPECIFIC_UP

6

1.76

0.002

P53PATHWAY

6

1.61

0.004

HSA04115_P53_SIGNALING_PATHWAY

13

1.62

0.006

P53GENES_ALL

9

1.53

0.021

P53_BRCA1_UP

5

1.50

0.030

STRESS_P53_SPECIFIC_UP

5

1.44

0.031

KANNAN_P53_UP

9

1.51

0.032

DNA_DAMAGE_SIGNALING

13

1.69

0.008

UVC_TTD-XPCS_COMMON_DN

8

1.69

0.014

CIS_XPC_DN

10

1.73

0.017

BLEO_HUMAN_LYMPH_HIGH_4HRS_UP

9

1.59

0.028

MOREAUX_TACI_HI_VS_LOW_UP

8

1.45

0.023

SMITH_HTERT_DN

5

1.57

0.028

ROTH_HTERT_DIFF

7

1.48

0.049

HINATA_NFKB_UP

6

1.53

0.032

APOPTOSIS

6

1.55

0.034

BRENTANI_DEATH

6

1.55

0.034

APOPTOSIS_GENMAPP

5

1.56

0.035

CELL_CYCLE_KEGG

6

1.52

0.044

CELL_CYCLE

6

1.52

0.044

TAKEDA_NUP8_HOXA9_16D_DN

11

1.43

0.045

Function/Pathway

Gene sets enriched in resistant patients

Size

NES

NOM p-val

GOLDRATH_HP

14

1.61

0.008

LE_MYELIN_UP

6

1.58

0.009

HSA05110_CHOLERA_INFECTION

5

1.63

0.023

CHAUHAN_2ME2

5

1.50

0.042

WERNER_FIBRO_DN

5

1.45

0.059

UVB_SCC_DN

6

1.39

0.086

MYC_ONCOGENIC_SIGNATURE

8

1.37

0.061

LEE_TCELLS2_UP

46

1.27

0.084

BYSTRYKH_HSC_TRANS_GLOCUS

29

1.38

0.070

SANSOM_APC_LOSS5_UP

10

1.47

0.084